Jay Patchen, MD
Internal Medicine · Memphis, TNNPI 1619940509
Payments from drug & device makers
Across 172 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$746
- AstraZeneca$551
- Boehringer Ingelheim$262
- Sanofi-aventis U.S. LLC$262
- Lilly USA, LLC$170
- Johnson & Johnson$115
- plus $617 from 13 others
What the payments were for
- Food & beverage$2,722100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $746 |
| AstraZeneca | 30 | $551 |
| Boehringer Ingelheim | 16 | $262 |
| Sanofi-aventis U.S. LLC | 17 | $262 |
| Lilly USA, LLC | 11 | $170 |
| Johnson & Johnson | 8 | $115 |
| Merck | 7 | $114 |
| Pfizer | 8 | $111 |
| GSK | 5 | $75 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Exact Sciences | 3 | $48 |
| AbbVie(2 entities) | 3 | $46 |
| Abbott | 2 | $45 |
| Bayer | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Mannkind Corporation | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Roche Diabetes Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$124
How this compares
$2,722 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $321,717 |
| JardianceEmpagliflozin | 106 | $108,740 |
| EliquisApixaban | 66 | $60,277 |
| TrulicityDulaglutide | 38 | $55,380 |
| MounjaroTirzepatide | 54 | $55,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $52,376 |
| FarxigaDapagliflozin Propanediol | 43 | $42,079 |
| JanuviaSitagliptin Phosphate | 28 | $30,121 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $28,816 |
| XareltoRivaroxaban | 21 | $22,773 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $17,402 |
| LinzessLinaclotide | 13 | $15,775 |
| GemtesaVibegron | 15 | $10,538 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $9,638 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $746 | $321,717245 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $262 | $116,487117 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $170 | $110,69992 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $75 | $85,479132 claims |
| PfizerEliquis | $111 | $60,27766 claims |
| AstraZenecaFarxiga | $551 | $42,07943 claims |
| MerckJanuvia | $114 | $30,12128 claims |
| Johnson & JohnsonXarelto | $115 | $22,77321 claims |
| AbbVieLinzess | $46 | $15,77513 claims |
| Sanofi-aventis U.S. LLCAmbien, Lantus | $262 | $9,43826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Memphis
- Phillip NorthcrossMemphis$39K
- Lawrence WhitlockMemphis$36K
- Angela WatsonMemphis$32K
- William CushmanMemphis$24K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.